Get Premium to unlock powerful stock data
NAS:AVXL (USA)  
Anavex Life Sciences Corp logo

Anavex Life Sciences Corp

$ 11.04 +0.74 (+7.18%) 10:08 PM EST
P/E:
At Loss
P/B:
5.62
Market Cap:
$ 854.60M
Enterprise V:
$ 643.97M
Volume:
1.10M
Avg Vol (2M):
966.42K
Also Trade In:
Volume:
1.10M
Market Cap $:
854.60M
PE Ratio:
At Loss
Avg Vol (2-Month):
966.42K
Enterprise Value $:
643.97M
PB Ratio:
5.62
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Anavex Life Sciences Corp
NAICS : 325412 SIC : 8731
51 West 52nd Street, 7th Floor, New York, NY, USA, 10019
Description
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.95
Interest Coverage No Debt
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 84.3
9-Day RSI 73.66
14-Day RSI 66.16
6-1 Month Momentum % -44.18
12-1 Month Momentum % -65.09

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 19.86
Quick Ratio 19.86
Cash Ratio 19

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -18.2
Name Current Vs Industry Vs History
ROE % -31.67
ROA % -29.65
ROIC % -4547.53
ROCE % -34.33

Financials (Next Earnings Date:2022-08-12 Est.)

AVXL's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:AVXL

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -0.57
Beta 0.49
Volatility % 51.61
14-Day RSI 66.16
14-Day ATR ($) 0.688676
20-Day SMA ($) 9.132
12-1 Month Momentum % -65.09
52-Week Range ($) 7.13 - 28.26
Shares Outstanding (Mil) 77.41

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Anavex Life Sciences Corp Filings

Document Form Filing Date
No Filing Data

Headlines

See More